Trial PROSPERs China’s fight against advancing prostate cancer
New results from the PROSPER trial helped persuade the Chinese government to approve enzalutamide for adult patients diagnosed with advanced non-metastatic castration-resistant prostate cancer,
Peter Doyle reports
It might be coincidental. But eight months after a joint study by the Peking First University Hospital and National Urological Cancer Center of China in Beijing found a lack of effective therapies in the world’s most populous country for patients with advanced prostate cancer, China’s medicine regulator, the National Medical Products Administration (NMPA), approved the oral androgen-receptor inhibitor enzalutamide for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.